Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group

Anna E. Teeter, Joseph C. Presti, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives: To examine the correlation between the prostate-specific antigen doubling time (PSADT) and overall survival (OS) and among men in the SEARCH database (an older, racially diverse cohort undergoing RP at multiple Veterans Affairs medical centers). Previous studies largely performed at tertiary care centers with relatively young, racially homogenous cohorts found a short PSADT on recurrence after RP portended a poor prognosis. Methods: We performed a Cox proportional hazards analysis to examine the correlation between postrecurrence PSADT and the interval from recurrence to OS and prostate cancer-specific mortality among 345 men in the SEARCH database who had undergone RP from 1988 to 2008. We examined the PSADT as a categorical variable using the clinically significant cutpoints of <3, 3-8.9, 9-14.9, and <15 months. Results: A PSADT of <3 months (hazard ratio 5.48, P = .002) was associated with poorer OS than a PSADT of <15 months. A trend was seen toward worse OS for the men with a PSADT of 3-8.9 months (hazard ratio 1.70, P = .07). PSADTs of <3 months (P < .001) and 3-8.9 months (P = .004) were associated with an increased risk of prostate cancer-specific mortality. Conclusions: In an older, racially diverse cohort, recurrence with a PSADT of <9 months was associated with worse all-cause mortality. The results of the present study have validated previous findings that PSADT is a useful tool for identifying men at increased risk of all-cause mortality early in their disease course.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalUrology
Volume77
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Databases
Survival
Mortality
Recurrence
Prostatic Neoplasms
Veterans
Tertiary Care Centers

ASJC Scopus subject areas

  • Urology

Cite this

Teeter, A. E., Presti, J. C., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., & Freedland, S. J. (2011). Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group. Urology, 77(1), 149-153. https://doi.org/10.1016/j.urology.2010.04.071

Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group. / Teeter, Anna E.; Presti, Joseph C.; Aronson, William J.; Terris, Martha K.; Kane, Christopher J.; Amling, Christopher L.; Freedland, Stephen J.

In: Urology, Vol. 77, No. 1, 01.01.2011, p. 149-153.

Research output: Contribution to journalArticle

Teeter, Anna E. ; Presti, Joseph C. ; Aronson, William J. ; Terris, Martha K. ; Kane, Christopher J. ; Amling, Christopher L. ; Freedland, Stephen J. / Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group. In: Urology. 2011 ; Vol. 77, No. 1. pp. 149-153.
@article{ffc983402b614464a2e774ed52677565,
title = "Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group",
abstract = "Objectives: To examine the correlation between the prostate-specific antigen doubling time (PSADT) and overall survival (OS) and among men in the SEARCH database (an older, racially diverse cohort undergoing RP at multiple Veterans Affairs medical centers). Previous studies largely performed at tertiary care centers with relatively young, racially homogenous cohorts found a short PSADT on recurrence after RP portended a poor prognosis. Methods: We performed a Cox proportional hazards analysis to examine the correlation between postrecurrence PSADT and the interval from recurrence to OS and prostate cancer-specific mortality among 345 men in the SEARCH database who had undergone RP from 1988 to 2008. We examined the PSADT as a categorical variable using the clinically significant cutpoints of <3, 3-8.9, 9-14.9, and <15 months. Results: A PSADT of <3 months (hazard ratio 5.48, P = .002) was associated with poorer OS than a PSADT of <15 months. A trend was seen toward worse OS for the men with a PSADT of 3-8.9 months (hazard ratio 1.70, P = .07). PSADTs of <3 months (P < .001) and 3-8.9 months (P = .004) were associated with an increased risk of prostate cancer-specific mortality. Conclusions: In an older, racially diverse cohort, recurrence with a PSADT of <9 months was associated with worse all-cause mortality. The results of the present study have validated previous findings that PSADT is a useful tool for identifying men at increased risk of all-cause mortality early in their disease course.",
author = "Teeter, {Anna E.} and Presti, {Joseph C.} and Aronson, {William J.} and Terris, {Martha K.} and Kane, {Christopher J.} and Amling, {Christopher L.} and Freedland, {Stephen J.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.urology.2010.04.071",
language = "English (US)",
volume = "77",
pages = "149--153",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Does PSADT after radical prostatectomy correlate with overall survival?-A report from the SEARCH database group

AU - Teeter, Anna E.

AU - Presti, Joseph C.

AU - Aronson, William J.

AU - Terris, Martha K.

AU - Kane, Christopher J.

AU - Amling, Christopher L.

AU - Freedland, Stephen J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objectives: To examine the correlation between the prostate-specific antigen doubling time (PSADT) and overall survival (OS) and among men in the SEARCH database (an older, racially diverse cohort undergoing RP at multiple Veterans Affairs medical centers). Previous studies largely performed at tertiary care centers with relatively young, racially homogenous cohorts found a short PSADT on recurrence after RP portended a poor prognosis. Methods: We performed a Cox proportional hazards analysis to examine the correlation between postrecurrence PSADT and the interval from recurrence to OS and prostate cancer-specific mortality among 345 men in the SEARCH database who had undergone RP from 1988 to 2008. We examined the PSADT as a categorical variable using the clinically significant cutpoints of <3, 3-8.9, 9-14.9, and <15 months. Results: A PSADT of <3 months (hazard ratio 5.48, P = .002) was associated with poorer OS than a PSADT of <15 months. A trend was seen toward worse OS for the men with a PSADT of 3-8.9 months (hazard ratio 1.70, P = .07). PSADTs of <3 months (P < .001) and 3-8.9 months (P = .004) were associated with an increased risk of prostate cancer-specific mortality. Conclusions: In an older, racially diverse cohort, recurrence with a PSADT of <9 months was associated with worse all-cause mortality. The results of the present study have validated previous findings that PSADT is a useful tool for identifying men at increased risk of all-cause mortality early in their disease course.

AB - Objectives: To examine the correlation between the prostate-specific antigen doubling time (PSADT) and overall survival (OS) and among men in the SEARCH database (an older, racially diverse cohort undergoing RP at multiple Veterans Affairs medical centers). Previous studies largely performed at tertiary care centers with relatively young, racially homogenous cohorts found a short PSADT on recurrence after RP portended a poor prognosis. Methods: We performed a Cox proportional hazards analysis to examine the correlation between postrecurrence PSADT and the interval from recurrence to OS and prostate cancer-specific mortality among 345 men in the SEARCH database who had undergone RP from 1988 to 2008. We examined the PSADT as a categorical variable using the clinically significant cutpoints of <3, 3-8.9, 9-14.9, and <15 months. Results: A PSADT of <3 months (hazard ratio 5.48, P = .002) was associated with poorer OS than a PSADT of <15 months. A trend was seen toward worse OS for the men with a PSADT of 3-8.9 months (hazard ratio 1.70, P = .07). PSADTs of <3 months (P < .001) and 3-8.9 months (P = .004) were associated with an increased risk of prostate cancer-specific mortality. Conclusions: In an older, racially diverse cohort, recurrence with a PSADT of <9 months was associated with worse all-cause mortality. The results of the present study have validated previous findings that PSADT is a useful tool for identifying men at increased risk of all-cause mortality early in their disease course.

UR - http://www.scopus.com/inward/record.url?scp=78650882949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650882949&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2010.04.071

DO - 10.1016/j.urology.2010.04.071

M3 - Article

C2 - 21145094

AN - SCOPUS:78650882949

VL - 77

SP - 149

EP - 153

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -